Medivir sharpens focus on late-stage liver cancer and rare bone disease programs

Medivir AB ( (SE:MVIR) ) has shared an announcement.

Medivir is sharpening its focus on two proprietary programs aimed at serious conditions lacking effective treatments, positioning itself in niche but significant segments of oncology and rare diseases. The company’s pipeline is anchored by fostroxacitabine bralpamide for liver cancer and MIV-711 for Osteogenesis Imperfecta, reflecting a strategy that blends internal development with strategic partnerships.

The newly published annual report outlines plans for a randomized phase 2 trial of fostrox in combination with Lenvima to validate earlier efficacy signals and support further advancement in liver cancer. A phase 2 study of MIV-711 is also planned to establish clinical proof of concept ahead of a potential registrational program in Osteogenesis Imperfecta, moves that could materially influence Medivir’s future growth prospects and strengthen its standing as a specialist developer in high-need therapeutic areas.

The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.

More about Medivir AB

Medivir AB is a Swedish biopharmaceutical company focused on developing innovative drugs for diseases with high unmet medical need. Its two lead programs are fostroxacitabine bralpamide, a liver-targeted inhibitor of DNA replication for liver cancer, and MIV-711 for Osteogenesis Imperfecta, both with potential to be first-in-class therapies. Founded in 1988, Medivir has previously brought Xerclear and Olysio to market, and its shares trade on Nasdaq Stockholm’s Small Cap list under the ticker MVIR.

Average Trading Volume: 9,900,567

Technical Sentiment Signal: Hold

Current Market Cap: SEK1.34B

See more insights into MVIR stock on TipRanks’ Stock Analysis page.